AU2015287227B2 - Immune-stimulating monoclonal antibodies against human interleukin-2 - Google Patents

Immune-stimulating monoclonal antibodies against human interleukin-2 Download PDF

Info

Publication number
AU2015287227B2
AU2015287227B2 AU2015287227A AU2015287227A AU2015287227B2 AU 2015287227 B2 AU2015287227 B2 AU 2015287227B2 AU 2015287227 A AU2015287227 A AU 2015287227A AU 2015287227 A AU2015287227 A AU 2015287227A AU 2015287227 B2 AU2015287227 B2 AU 2015287227B2
Authority
AU
Australia
Prior art keywords
seq
antibody
binding
fragment
hil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015287227A
Other languages
English (en)
Other versions
AU2015287227A1 (en
AU2015287227A8 (en
Inventor
Natalia Arenas-Ramirez
Onur Boyman
Chao ZOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universität
Original Assignee
Zurich Universität
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universität filed Critical Zurich Universität
Publication of AU2015287227A1 publication Critical patent/AU2015287227A1/en
Publication of AU2015287227A8 publication Critical patent/AU2015287227A8/en
Assigned to UNIVERSITAT ZURICH reassignment UNIVERSITAT ZURICH Request for Assignment Assignors: NOVARTIS AG, UNIVERSITAT ZURICH
Application granted granted Critical
Publication of AU2015287227B2 publication Critical patent/AU2015287227B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015287227A 2014-07-10 2015-07-10 Immune-stimulating monoclonal antibodies against human interleukin-2 Ceased AU2015287227B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14176619 2014-07-10
EP14176619.6 2014-07-10
PCT/IB2015/055226 WO2016005950A1 (en) 2014-07-10 2015-07-10 Immune-stimulating monoclonal antibodies against human interleukin-2

Publications (3)

Publication Number Publication Date
AU2015287227A1 AU2015287227A1 (en) 2017-02-09
AU2015287227A8 AU2015287227A8 (en) 2017-02-16
AU2015287227B2 true AU2015287227B2 (en) 2021-02-18

Family

ID=51162588

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015287227A Ceased AU2015287227B2 (en) 2014-07-10 2015-07-10 Immune-stimulating monoclonal antibodies against human interleukin-2

Country Status (9)

Country Link
US (2) US10894828B2 (enExample)
EP (2) EP3693389B1 (enExample)
JP (1) JP7209464B2 (enExample)
CN (1) CN106604932B (enExample)
AU (1) AU2015287227B2 (enExample)
CA (1) CA2954476C (enExample)
DK (1) DK3166973T3 (enExample)
ES (2) ES2989669T3 (enExample)
WO (1) WO2016005950A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6993699B2 (ja) * 2016-01-11 2022-02-03 ウニヴェルズィテート・ツューリヒ ヒトインターロイキン－２に対する免疫刺激性ヒト化モノクローナル抗体及びその融合タンパク質
US10858428B2 (en) 2016-09-28 2020-12-08 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
GB201621806D0 (en) * 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
WO2018156955A1 (en) * 2017-02-23 2018-08-30 City Of Hope Methods for in vivo expansion of cd8+ t cells and prevention or treatment of gvhd
MX2019011252A (es) * 2017-03-23 2020-01-23 Univ Pennsylvania Anticuerpos anti-c5a y usos de los mismos.
AU2018271751B2 (en) * 2017-05-25 2021-04-01 Institute For Basic Science Anti-human interleukin-2 antibodies and uses thereof
CA3094329A1 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
CN115768483A (zh) 2020-01-13 2023-03-07 西纳福克斯股份有限公司 抗体与免疫细胞衔接器的缀合物
MX2022010034A (es) * 2020-02-16 2022-12-13 Aulos Bioscience Inc Anticuerpos anti-il-2 diseñados.
KR102986821B1 (ko) * 2020-04-22 2026-07-06 머크 샤프 앤드 돔 엘엘씨 인터류킨-2 수용체 베타 감마c 이량체에 대해 편향되고 비펩티드성 수용성 중합체에 접합된 인간 인터류킨-2 접합체
US12692306B2 (en) * 2020-08-18 2026-07-28 Universität Zürich CD25-biased anti-IL-2 antibody
CN116783213A (zh) * 2020-08-18 2023-09-19 苏黎世大学 Cd25偏向的抗il‐2抗体
JP2024506022A (ja) 2021-02-08 2024-02-08 シンアフィックス ビー．ブイ． 多機能性抗体
CA3234995A1 (en) 2021-10-14 2023-04-20 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
US11773160B1 (en) 2022-08-05 2023-10-03 Anaveon AG Immune-stimulating IL-2 fusion proteins
CN119912559B (zh) * 2025-01-22 2025-12-26 贵州中医药大学 一种新冠病毒变异株jn.1刺突s蛋白的单链抗体及其应用
CN119775409B (zh) * 2025-03-05 2025-07-11 深圳真实生物医药科技有限公司 靶向sost的抗体及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007095643A2 (en) * 2006-02-16 2007-08-23 Nascent Biologics, Inc. Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210634A (en) 1983-12-23 1989-05-29 Hoffmann La Roche Purification of recombinant human interleukin - 2; pharmaceutical compositions
DK134487A (da) * 1986-03-17 1987-09-18 Hoffmann La Roche Monoklonalt antistof med affinitet for humant interleukin-2
DK0920505T3 (da) 1996-08-16 2008-09-08 Schering Corp Pattedyrcelleoverfladeantigener og tilhörende reagenser
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US7387271B2 (en) 2002-12-30 2008-06-17 3M Innovative Properties Company Immunostimulatory combinations
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
CN101189265B (zh) * 2005-06-01 2012-07-04 米克罗麦特股份公司 抗il2抗体
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
CN101045923B (zh) * 2006-03-31 2011-11-23 沈阳三生制药有限责任公司 生产一种白细胞介素类似物的方法
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
SI3339323T1 (sl) 2010-08-12 2019-12-31 Eli Lilly And Company Protitelesa proti N3PGLU amiloid beta peptidu in njihove uporabe
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
WO2013157105A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
WO2015109212A1 (en) * 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007095643A2 (en) * 2006-02-16 2007-08-23 Nascent Biologics, Inc. Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject

Also Published As

Publication number Publication date
US10894828B2 (en) 2021-01-19
EP3166973A1 (en) 2017-05-17
US20170183403A1 (en) 2017-06-29
EP3693389A9 (en) 2021-04-07
EP3693389C0 (en) 2024-09-04
AU2015287227A1 (en) 2017-02-09
DK3166973T3 (da) 2020-04-06
JP2017525343A (ja) 2017-09-07
AU2015287227A8 (en) 2017-02-16
US20210230269A1 (en) 2021-07-29
EP3166973B1 (en) 2020-02-19
CA2954476C (en) 2023-09-19
CN106604932A (zh) 2017-04-26
ES2989669T3 (es) 2024-11-27
JP7209464B2 (ja) 2023-01-20
ES2779977T3 (es) 2020-08-21
EP3693389A1 (en) 2020-08-12
EP3693389B1 (en) 2024-09-04
WO2016005950A1 (en) 2016-01-14
CN106604932B (zh) 2024-12-10
CA2954476A1 (en) 2016-01-14

Similar Documents

Publication Publication Date Title
US20210230269A1 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
CN113166246B (zh) 一种抗体及其用途
KR102662387B1 (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
CN109843927B (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
CN111744013B (zh) 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
CN114746440A (zh) 新型多肽复合物
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
KR20200063147A (ko) Pdl1 표적화 항체 및 이의 사용 방법
CN111492066A (zh) 使用转录本进行抗体方向的方法及由其衍生的组合物
WO2024017326A1 (zh) 抗gprc5d纳米抗体及其应用
CN110590952A (zh) 一种抗ca125糖类抗原的高亲和力纳米抗体及其应用
CN121152800A (zh) 特异性结合Claudin18.2的抗体及其制法和应用
CN111375059A (zh) 一种抗gitr抗体药物组合物及其用途
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
CN118355032A (zh) Bcma抗体及其应用
CN111788229A (zh) Csf1r结合剂
Zhao et al. Generation of anti-idiotype scFv for pharmacokinetic measurement in lymphoma patients treated with chimera anti-CD22 antibody SM03
TWI889766B (zh) 抗cd19抗體以及使用與製造其的方法
WO2023245022A2 (en) Multispecific binding agents that target b7h3 and gd2 and uses thereof
HK40049006A (en) Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof
HK40049006B (en) Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof
HK40076302B (en) New polypeptide complex

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 31 , NO 5 , PAGE(S) 794 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME NOVARTIS AG; UNIVERSITAT ZURICH PROREKTORAT MNW, APPLICATION NO. 2015287227, UNDER INID (71) CORRECT THE CO-APPLICANT NAME TO UNIVERSITAT ZURICH

Free format text: IN VOL 31 , NO 5 , PAGE(S) 794 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME NOVARTIS AG; UNIVERSITAT ZURICH PROREKTORAT MNW, APPLICATION NO. 2015287227, UNDER INID (71) CORRECT THE CO-APPLICANT NAME TO UNIVERSITAT ZURICH

PC1 Assignment before grant (sect. 113)

Owner name: UNIVERSITAT ZURICH

Free format text: FORMER APPLICANT(S): NOVARTIS AG; UNIVERSITAT ZURICH

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired